SeekingAlphaSeptember 4, 2026 at 3:15 AM NY20 hours ago
Bristol Myers Squibb: Buy The Growth Portfolio At A Value Price
Bristol Myers Squibb's growth portfolio now drives nearly 60% of revenue, offsetting legacy drug declines and supporting total revenue growth. See why BMY stock is a Buy.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — SeekingAlpha
Companies in This Story
Related Stories
Jim Cramer Thinks This Struggling Stock Could See A “Big Earnings Acceleration”
Yahoo3 hours ago
Walmart, Target, and Kroger face growing retail crime issue
Yahoo3 hours ago
Cramer Says a Wave of 21 Year Olds on Robinhood Is the Only Reason This Market Has Not Cracked
Yahoo5 hours ago
Top Research Reports for Apple, Broadcom & Shell
Yahoo6 hours ago
Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?
Yahoo6 hours ago